Citius Oncology (CTOR) AI Stock Analysis

• Market Cap: $71.14M
• Dividend Yield: N/A
• Average Volume (3M): 324.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.70
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): -0.06
• Shares Outstanding: 88,275,210
• 10 Day Avg. Volume: 692,334
• 30 Day Avg. Volume: 324,922
• PEG Ratio: -0.45
• Price to Book (P/B): 3.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -27.08
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 16.25
• Enterprise Value/Gross Profit: 20.31
• Enterprise Value/Ebitda: -2.95
• 1Y Price Target: $6.00
• Price Target Upside: 460.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.14
• Revenue Forecast (FY): $38.87M

• Rating: 48 Neutral
• Price Target: $0.80 ▼(-24.86% Downside)
• Action: Reiterated Date: 03/10/26
• Date: Action: Reiterated 03/10/26

Score is held down primarily by weak financial performance (no revenue, widening losses, and increasing cash burn) and bearish technical positioning (price below key moving averages with negative MACD). Positive corporate updates (Phase 1 data and recent financing) provide some offset, while valuation metrics are not very informative due to negative earnings and no dividend.

Positive Factors

Promising Phase 1 combo data

Investigator-led Phase 1 combination data showed objective responses and clinical benefit with no unexpected safety signals. These durable efficacy and safety signals support moving LYMPHIR into Phase 2 combination studies, expanding addressable indications and strengthening long-term commercialization prospects.

Low financial leverage

Relatively low debt provides structural financial flexibility for a clinical-stage company, lowering near-term insolvency risk and preserving the ability to raise non-distressed capital or negotiate partnerships while advancing clinical programs over the next several quarters.

Recent $18M financing supports runway

The December 2025 financing materially extends operational runway and reduces immediate liquidity pressure, enabling ongoing trials and business development. This structural capital infusion lowers near-term dilution pressure and supports execution of clinical milestones.

Negative Factors

Pre-revenue with widening losses

CTOR remains pre-revenue while operating losses have widened materially, eroding equity. Without product revenues or regulatory approvals, persistent negative earnings strain resources and increase reliance on external funding over the medium term.

Rising cash burn and negative FCF

Operating and free cash flow deteriorated meaningfully in 2025, indicating increasing cash consumption to fund trials. This structural cash burn raises the probability of future financings and can dilute shareholders or constrain development if capital markets tighten.

Efficacy still unproven in early trials

Phase 1 studies produced encouraging signals but were small and not designed to confirm efficacy. Lasting commercial success requires larger, controlled trials and regulatory clarity, meaning clinical and approval risk remains a material long-term constraint.

Citius Oncology Business Overview & Revenue Model

Company Description

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

How the Company Makes Money

null

Citius Oncology Financial Statement Overview

Summary

Pre-revenue profile with materially widening losses (EBIT deteriorating to about -$23.5M in 2025 annual) and worsening cash burn (free cash flow about -$11.2M in 2025 annual). Low leverage (debt-to-equity ~0.08–0.09) is a partial offset, but continued equity erosion and funding risk weigh heavily.

Income Statement

CTOR remains a pre-revenue oncology company (revenue is $0 across all annual periods provided), so operating losses drive results. Losses have widened materially, with EBIT declining from about -$4.9M (2022) to -$23.5M (2025 annual), and net income also deteriorating to about -$24.8M (2025 annual) versus -$5.4M (2022). With no revenue base yet, profitability and margin indicators are not meaningful, and the trajectory points to rising spend ahead of commercialization.

Balance Sheet

The balance sheet shows relatively low leverage, with total debt of about $3.8M in 2024–2025 annual and a low debt-to-equity ratio (~0.08–0.09), which is a positive for financial flexibility. However, equity has drifted down (from ~$46.1M in 2024 to ~$44.9M in 2025 annual), consistent with ongoing losses, and returns on equity are deeply negative (roughly -46% to -55% in 2024–2025 annual). Total assets increased to ~$100.9M in 2025 annual, but the key risk is continued equity erosion if losses persist.

Cash Flow

Cash generation is weak and worsening. Operating cash flow swung from slightly positive in 2024 annual (~$0.1M) to meaningfully negative in 2025 annual (~-$5.5M), and free cash flow is consistently negative, expanding to ~-$11.2M in 2025 annual from ~-$4.9M in 2024 annual. While free cash flow can diverge from net losses due to timing and non-cash items, the overall pattern indicates increasing cash burn, which raises the likelihood of future financing needs absent a revenue inflection.

Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022
Income Statement
Total Revenue	3.94M	0.00	0.00	0.00	0.00
Gross Profit	3.15M	0.00	0.00	0.00	0.00
EBITDA	-21.74M	-23.49M	-20.57M	-12.12M	0.00
Net Income	-23.64M	-24.76M	-21.15M	-12.70M	-10.87M
Balance Sheet
Total Assets	109.97M	100.94M	84.37M	47.73M	42.69M
Cash, Cash Equivalents and Short-Term Investments	7.30M	3.92M	112.00	0.00	0.00
Total Debt	3.80M	3.80M	3.80M	0.00	0.00
Total Liabilities	51.56M	56.08M	38.23M	22.20M	6.42M
Stockholders Equity	58.41M	44.87M	46.14M	25.54M	36.27M
Cash Flow
Free Cash Flow	-12.89M	-5.49M	126.35K	-601.30K	-47.97K
Operating Cash Flow	-12.89M	-5.49M	126.35K	-601.30K	-47.97K
Investing Cash Flow	-10.19M	-5.75M	-5.00M	-1.32M	-67.32M
Financing Cash Flow	30.41M	15.17M	4.87M	1.66M	67.66M

Citius Oncology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTOR, the sentiment is Negative. The current price of 1.07 is above the 20-day moving average (MA) of 1.05, below the 50-day MA of 1.09, and below the 200-day MA of 1.63, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 22.49 is Positive, neither overbought nor oversold. The STOCH value of 9.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTOR.

Citius Oncology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIIB	64 Neutral	$26.89B	―	7.28%	―	5.00%	-1.03%
GRFS	56 Neutral	$6.58B	14.03	7.56%	1.56%	9.45%	167.00%
OGN	52 Neutral	$1.65B	9.95	25.50%	4.80%	-1.69%	-61.89%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CTOR	48 Neutral	$71.14M	-3.95	-55.19%	―	―	―
SRXH	40 Underperform	$43.63M	-0.22	435.85%	―	-8.12%	―

Citius Oncology Corporate Events

Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data

On March 10, 2026, Citius Oncology reported positive topline data from a completed investigator-initiated Phase 1 trial led by University of Pittsburgh researchers evaluating LYMPHIR in combination with pembrolizumab in patients with recurrent or refractory gynecologic cancers. The non-chemotherapy dose-escalation study in 25 evaluable patients showed no unexpected safety signals or serious immune-related adverse events at any dose level.

Among 21 evaluable patients, the trial recorded a 24% objective response rate and a 48% clinical benefit rate, suggesting the LYMPHIR–pembrolizumab regimen may enhance anti-tumor activity in a population with poor prognosis and limited treatment options. While the Phase 1 design was not powered to establish efficacy, the early signal supports further exploration in Phase 2 settings and underscores LYMPHIR’s potential to address a significant unmet need in relapsed or refractory ovarian and endometrial cancers, where current immunotherapies have had limited impact.

The most recent analyst rating on (CTOR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.

Citius Oncology Announces Positive Phase 1 LYMPHIR Data

On March 4, 2026, Citius Oncology reported positive topline safety and efficacy data from an investigator-initiated Phase 1 trial of LYMPHIR administered before commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma patients. The study, led by investigators at the University of Minnesota and City of Hope, aimed to enhance standard lymphodepletion by using LYMPHIR to deplete regulatory T-cells ahead of CAR-T infusion.

All 14 enrolled patients completed LYMPHIR dosing and proceeded to CAR-T treatment, with the regimen showing no dose-limiting toxicities and no Grade 3 or higher LYMPHIR-related immune adverse events or infusion reactions. Investigators reported effective Treg depletion in nearly all participants and an 86% overall response rate at one month, including 57% complete and 29% partial responses, alongside one-year progression-free and overall survival rates of 77% and 84%, respectively.

Adverse events associated with LYMPHIR, such as low-grade capillary leak syndrome, fever and transient liver enzyme elevations, were described as manageable, while higher-grade cytopenias aligned with expected lymphodepletion effects and CAR-T-related toxicities were limited to low-grade cytokine release syndrome and neurotoxicity. While the Phase 1 trial was not designed or powered to determine definitive efficacy or long-term comparative outcomes, the data bolster Citius Oncology’s strategy to position LYMPHIR as an immunomodulatory adjunct to existing cancer therapies, potentially expanding its role beyond its current CTCL indication and reinforcing the company’s footprint in the immuno-oncology market.

The most recent analyst rating on (CTOR) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.